Skip to main content
Top
Published in: BMC Infectious Diseases 1/2022

Open Access 01-12-2022 | Hepatitis B | Research

Trends in hepatitis B notification rates in Guangzhou, China, between 2009 and 2020: an epidemiological study

Authors: Wei Liu, Zhiqiang Dong, Wensui Hu, Ke Li, Lili Sun, Jianrong Hou, Shijie Jia, Yuan Liu

Published in: BMC Infectious Diseases | Issue 1/2022

Login to get access

Abstract

Background

Although the prevalence of hepatitis B in Guangzhou, China, is high, the epidemiological trends are not well-documented. We aimed to analyse newly reported hepatitis B cases in Guangzhou between 2009 and 2020 to explore the epidemiological trends and provide insights for the development of control measures.

Methods

Information on the population and new cases of hepatitis B in Guangzhou between 2009 and 2020 was obtained from the China Information System for Disease Control and Prevention, which was used to calculate the annual notification rates of hepatitis B by sex, age group (0–9; 10–19; 20–29; 30–39; 40–49; 50–59; ≥ 60 years), and location (urban or rural). Joinpoint regression analysis was used to analyse the temporal trends and calculate the average annual percentage change (AAPC) and annual percentage change (APC) for each identified trend line segment.

Results

Between 2009 and 2020, 287,034 new cases of hepatitis B were cumulatively reported. The average annual notification rate was 181.13/100,000, and the notification rate showed a long-term downward trend during the period 2009–2020, with an annual decrease of 6.30% (APC − 6.30%; 95% CI − 7.56 to − 5.02%). Men had a significantly higher notification rate than women; however, the sex ratio decreased from a maximum of 2.34 in 2010 to a minimum of 1.54 in 2020. A downward trend in the notification rate was observed in urban areas and an upward trend was observed in rural areas, with an increase in the rural/urban ratio from 0.46 in 2012 to 1.57 in 2020. The notification rate for all age groups showed a decreasing trend from 2009, with the exception of the 50–59 years and ≥ 60 years groups, whose notification rates began to decrease from 2014 and 2015, respectively.

Conclusions

Although the overall notification rate of hepatitis B in Guangzhou decreased annually, it remained high. Further, in rural areas, the notification rate has been increasing, and effective measures should be taken to control hepatitis B infection in Guangzhou.
Literature
1.
go back to reference Zhang Q, Qi W, Wang X, Zhang Y, Xu Y, Qin S, Zhao P, Guo H, Jiao J, Zhou C, et al. Epidemiology of hepatitis B and hepatitis C infections and benefits of programs for hepatitis prevention in Northeastern China: a cross-sectional study. Clin Infect Dis. 2016;62(3):305–12.CrossRef Zhang Q, Qi W, Wang X, Zhang Y, Xu Y, Qin S, Zhao P, Guo H, Jiao J, Zhou C, et al. Epidemiology of hepatitis B and hepatitis C infections and benefits of programs for hepatitis prevention in Northeastern China: a cross-sectional study. Clin Infect Dis. 2016;62(3):305–12.CrossRef
2.
go back to reference Delaney WE, Borroto-Esoda K. Therapy of chronic hepatitis B: trends and developments. Curr Opin Pharmacol. 2008;8(5):532–40.CrossRef Delaney WE, Borroto-Esoda K. Therapy of chronic hepatitis B: trends and developments. Curr Opin Pharmacol. 2008;8(5):532–40.CrossRef
3.
4.
go back to reference Peng T, Cai Q, Yang M, Chen S, Chen F, Wang M, Peng L, Wong G, Shen C, Cheng W, et al. Epidemiological trends and virological traits of hepatitis B virus infection in pregnant women and neonates. Arch Virol. 2019;164(5):1335–41.CrossRef Peng T, Cai Q, Yang M, Chen S, Chen F, Wang M, Peng L, Wong G, Shen C, Cheng W, et al. Epidemiological trends and virological traits of hepatitis B virus infection in pregnant women and neonates. Arch Virol. 2019;164(5):1335–41.CrossRef
5.
go back to reference Arciuolo RJ, Lazaroff JE, Rosen JB, Lim S, Zucker JR. Trends in hepatitis B surveillance among pregnant women in New York City, 1998–2015. Public Health Rep. 2020;135(5):676–84.CrossRef Arciuolo RJ, Lazaroff JE, Rosen JB, Lim S, Zucker JR. Trends in hepatitis B surveillance among pregnant women in New York City, 1998–2015. Public Health Rep. 2020;135(5):676–84.CrossRef
6.
go back to reference Al Romaihi HE, Ganesan N, Farag EA, Smatti MK, Nasrallah GK, Himatt SM, Derbala MF, Alshamali M, Mahadoon LK, Khogali HS, et al. Demographics and epidemiology of hepatitis B in the State of Qatar: a five-year surveillance-based incidence study. Pathogens. 2019;8(2):68.CrossRef Al Romaihi HE, Ganesan N, Farag EA, Smatti MK, Nasrallah GK, Himatt SM, Derbala MF, Alshamali M, Mahadoon LK, Khogali HS, et al. Demographics and epidemiology of hepatitis B in the State of Qatar: a five-year surveillance-based incidence study. Pathogens. 2019;8(2):68.CrossRef
8.
go back to reference Khazaei S, Karami M, Ayubi E, Mohammadbeigi A, Hasanbeigi A, Mansori K, Mir-Shekar MR. Trends in epidemiology of hepatitis B and C infections in ilam province: national notifiable diseases surveillance system data. Caspian J Intern Med. 2018;9(1):16–21. Khazaei S, Karami M, Ayubi E, Mohammadbeigi A, Hasanbeigi A, Mansori K, Mir-Shekar MR. Trends in epidemiology of hepatitis B and C infections in ilam province: national notifiable diseases surveillance system data. Caspian J Intern Med. 2018;9(1):16–21.
9.
go back to reference Lok ASF, McMahon BJ. Chronic hepatitis B. Hepatology Baltimore, Md. 2007;45(2):507–39.CrossRef Lok ASF, McMahon BJ. Chronic hepatitis B. Hepatology Baltimore, Md. 2007;45(2):507–39.CrossRef
11.
go back to reference Stanaway JD, Flaxman AD, Naghavi M, Fitzmaurice C, Vos T, Abubakar I, Abu-Raddad LJ, Assadi R, Bhala N, Cowie B, et al. The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. Lancet. 2016;388(10049):1081–8.CrossRef Stanaway JD, Flaxman AD, Naghavi M, Fitzmaurice C, Vos T, Abubakar I, Abu-Raddad LJ, Assadi R, Bhala N, Cowie B, et al. The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. Lancet. 2016;388(10049):1081–8.CrossRef
12.
go back to reference Chang M, Liaw Y. Hepatitis B flares in chronic hepatitis B: pathogenesis, natural course, and management. J Hepatol. 2014;61(6):1407–17.CrossRef Chang M, Liaw Y. Hepatitis B flares in chronic hepatitis B: pathogenesis, natural course, and management. J Hepatol. 2014;61(6):1407–17.CrossRef
13.
go back to reference McMahon BJ. The natural history of chronic hepatitis B virus infection. Hepatology. 2009;49(S5):S45–55.CrossRef McMahon BJ. The natural history of chronic hepatitis B virus infection. Hepatology. 2009;49(S5):S45–55.CrossRef
14.
go back to reference McMahon BJ. Natural history of chronic hepatitis B. Clin Liver Dis. 2010;14(3):381–96.CrossRef McMahon BJ. Natural history of chronic hepatitis B. Clin Liver Dis. 2010;14(3):381–96.CrossRef
15.
go back to reference Abara WE, Qaseem A, Schillie S, McMahon BJ, Harris AM, Abraham GM, Centor R, DeLong DM, Gantzer HE, Horwitch CA, et al. Hepatitis B vaccination, screening, and linkage to care: best practice advice from the American College of Physicians and the Centers for Disease Control and Prevention. Ann Intern Med. 2017;167(11):794–804.CrossRef Abara WE, Qaseem A, Schillie S, McMahon BJ, Harris AM, Abraham GM, Centor R, DeLong DM, Gantzer HE, Horwitch CA, et al. Hepatitis B vaccination, screening, and linkage to care: best practice advice from the American College of Physicians and the Centers for Disease Control and Prevention. Ann Intern Med. 2017;167(11):794–804.CrossRef
16.
go back to reference Liang X, Bi S, Yang W, Wang L, Cui G, Cui F, Zhang Y, Liu J, Gong X, Chen Y, et al. Epidemiological serosurvey of hepatitis B in China—declining HBV prevalence due to hepatitis B vaccination. VACCINE. 2009;27(47):6550–7.CrossRef Liang X, Bi S, Yang W, Wang L, Cui G, Cui F, Zhang Y, Liu J, Gong X, Chen Y, et al. Epidemiological serosurvey of hepatitis B in China—declining HBV prevalence due to hepatitis B vaccination. VACCINE. 2009;27(47):6550–7.CrossRef
17.
go back to reference Ming W, Liu J, Cai Y, Xu J, Xu J, Cao Y, Yun X, Zhang X, Ni L, Zhang C. An investigation on the epidemiological characteristics of hepatitis B in Guangzhou. Chin J Epidemiol. 2009;30(12):1317–8. Ming W, Liu J, Cai Y, Xu J, Xu J, Cao Y, Yun X, Zhang X, Ni L, Zhang C. An investigation on the epidemiological characteristics of hepatitis B in Guangzhou. Chin J Epidemiol. 2009;30(12):1317–8.
19.
go back to reference Wang Z, Chen Y, Pan J. Trends of acute hepatitis B notification rates in Eastern China from 2005 to 2013. PLoS ONE. 2014;9(12): e114645.CrossRef Wang Z, Chen Y, Pan J. Trends of acute hepatitis B notification rates in Eastern China from 2005 to 2013. PLoS ONE. 2014;9(12): e114645.CrossRef
20.
go back to reference Zhang M, Wu R, Xu H, Uhanova J, Gish R, Wen X, Jin Q, Gerald MY, Nguyen MH, Gao Y, et al. Changing incidence of reported viral hepatitis in China from 2004 to 2016: an observational study. BMJ Open. 2019;9(8): e28248.CrossRef Zhang M, Wu R, Xu H, Uhanova J, Gish R, Wen X, Jin Q, Gerald MY, Nguyen MH, Gao Y, et al. Changing incidence of reported viral hepatitis in China from 2004 to 2016: an observational study. BMJ Open. 2019;9(8): e28248.CrossRef
21.
go back to reference Liu Z, Yang Q, Shi O, Ye W, Chen X, Zhang T. The epidemiology of hepatitis B and hepatitis C infections in China from 2004 to 2014: an observational population-based study. J Viral Hepatitis. 2018;25(12):1543–54.CrossRef Liu Z, Yang Q, Shi O, Ye W, Chen X, Zhang T. The epidemiology of hepatitis B and hepatitis C infections in China from 2004 to 2014: an observational population-based study. J Viral Hepatitis. 2018;25(12):1543–54.CrossRef
23.
go back to reference Fanning GC, Zoulim F, Hou J, Bertoletti A. Therapeutic strategies for hepatitis B virus infection: towards a cure. Nat Rev Drug Discov. 2019;18(11):827–44.CrossRef Fanning GC, Zoulim F, Hou J, Bertoletti A. Therapeutic strategies for hepatitis B virus infection: towards a cure. Nat Rev Drug Discov. 2019;18(11):827–44.CrossRef
24.
go back to reference World Health Organization: Global hepatitis report 2017. World Health Organization: Global hepatitis report 2017.
25.
go back to reference Cooke GS, Andrieux-Meyer I, Applegate TL, Atun R, Burry JR, Cheinquer H, Dusheiko G, Feld JJ, Gore C, Griswold MG, et al. Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission. Lancet Gastroenterol Hepatol. 2019;4(2):135–84.CrossRef Cooke GS, Andrieux-Meyer I, Applegate TL, Atun R, Burry JR, Cheinquer H, Dusheiko G, Feld JJ, Gore C, Griswold MG, et al. Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission. Lancet Gastroenterol Hepatol. 2019;4(2):135–84.CrossRef
26.
go back to reference Cui F, Shen L, Li L, Wang H, Wang F, Bi S, Liu J, Zhang G, Wang F, Zheng H, et al. Prevention of chronic hepatitis B after 3 decades of escalating vaccination policy, China. Emerg Infect Dis. 2017;23(5):765–72.CrossRef Cui F, Shen L, Li L, Wang H, Wang F, Bi S, Liu J, Zhang G, Wang F, Zheng H, et al. Prevention of chronic hepatitis B after 3 decades of escalating vaccination policy, China. Emerg Infect Dis. 2017;23(5):765–72.CrossRef
27.
go back to reference Yanbiao Z, Yan L, Xu X, Fan Y, Hanwu M, Jinquan C. Risk of hepatitis B virus infection among residents in Shenzhen city. Chin J Public Health. 2012;28(05):583–5. Yanbiao Z, Yan L, Xu X, Fan Y, Hanwu M, Jinquan C. Risk of hepatitis B virus infection among residents in Shenzhen city. Chin J Public Health. 2012;28(05):583–5.
28.
go back to reference Yanshan C, Duanhua Z, Yufei L, Lei L, Jichuan S, Weisi L, Pengzhou Q, Xuehong W, Xiongfei C. Analysis of risk factors of hepatitis B virus infections. J Trop Med. 2005;02:333–5. Yanshan C, Duanhua Z, Yufei L, Lei L, Jichuan S, Weisi L, Pengzhou Q, Xuehong W, Xiongfei C. Analysis of risk factors of hepatitis B virus infections. J Trop Med. 2005;02:333–5.
29.
go back to reference Liu J, Liang W, Jing W, Liu M. Countdown to 2030: eliminating hepatitis B disease, China. Bull World Health Organ. 2019;97(3):230–8.CrossRef Liu J, Liang W, Jing W, Liu M. Countdown to 2030: eliminating hepatitis B disease, China. Bull World Health Organ. 2019;97(3):230–8.CrossRef
30.
go back to reference Schillie S, Vellozzi C, Reingold A, Harris A, Haber P, Ward JW, Nelson NP. Prevention of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization practices. MMWR Recomm Rep. 2018;67(1):1–31.CrossRef Schillie S, Vellozzi C, Reingold A, Harris A, Haber P, Ward JW, Nelson NP. Prevention of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization practices. MMWR Recomm Rep. 2018;67(1):1–31.CrossRef
31.
go back to reference Control ECFD: Hepatitis B Annual Epidemiological Report for 2018. Stockholm: ECDC 2020. Control ECFD: Hepatitis B Annual Epidemiological Report for 2018. Stockholm: ECDC 2020.
32.
go back to reference Tanaka J, Akita T, Ko K, Miura Y, Satake M. Countermeasures against viral hepatitis B and C in Japan: an epidemiological point of view. Hepatol Res. 2019;49(9):990–1002.CrossRef Tanaka J, Akita T, Ko K, Miura Y, Satake M. Countermeasures against viral hepatitis B and C in Japan: an epidemiological point of view. Hepatol Res. 2019;49(9):990–1002.CrossRef
33.
go back to reference Shi JF, Cao M, Wang Y, Bai FZ, Lei L, Peng J, Feletto E, Canfell K, Qu C, Chen W. Is it possible to halve the incidence of liver cancer in China by 2050? Int J Cancer. 2021;148(5):1051–65.CrossRef Shi JF, Cao M, Wang Y, Bai FZ, Lei L, Peng J, Feletto E, Canfell K, Qu C, Chen W. Is it possible to halve the incidence of liver cancer in China by 2050? Int J Cancer. 2021;148(5):1051–65.CrossRef
34.
go back to reference Liu Z, Jiang Y, Yuan H, Fang Q, Cai N, Suo C, Jin L, Zhang T, Chen X. The trends in incidence of primary liver cancer caused by specific etiologies: results from the Global Burden of Disease Study 2016 and implications for liver cancer prevention. J Hepatol. 2019;70(4):674–83.CrossRef Liu Z, Jiang Y, Yuan H, Fang Q, Cai N, Suo C, Jin L, Zhang T, Chen X. The trends in incidence of primary liver cancer caused by specific etiologies: results from the Global Burden of Disease Study 2016 and implications for liver cancer prevention. J Hepatol. 2019;70(4):674–83.CrossRef
35.
go back to reference Baig S. Gender disparity in infections of Hepatitis B virus. J Coll Phys Surg-Pakistan. 2009;19(9):598. Baig S. Gender disparity in infections of Hepatitis B virus. J Coll Phys Surg-Pakistan. 2009;19(9):598.
36.
go back to reference Stawinska-Witoszynska B, Klos J, Moryson W, Wieckowska B. Trends in the incidence of acute hepatitis B in the polish population and their determinants. Medicina. 2021;57(8):738.CrossRef Stawinska-Witoszynska B, Klos J, Moryson W, Wieckowska B. Trends in the incidence of acute hepatitis B in the polish population and their determinants. Medicina. 2021;57(8):738.CrossRef
37.
go back to reference Rimšelienė G, Nilsen Ø, Kløvstad H, Blystad H, Aavitsland P. Epidemiology of acute and chronic hepatitis B virus infection in Norway, 1992–2009. BMC Infect Dis. 2011;11(1):153.CrossRef Rimšelienė G, Nilsen Ø, Kløvstad H, Blystad H, Aavitsland P. Epidemiology of acute and chronic hepatitis B virus infection in Norway, 1992–2009. BMC Infect Dis. 2011;11(1):153.CrossRef
38.
go back to reference Marschall T, Kretzschmar M, Mangen MJ, Schalm S. High impact of migration on the prevalence of chronic hepatitis B in the Netherlands. Eur J Gastroenterol Hepatol. 2008;20(12):1214–25.CrossRef Marschall T, Kretzschmar M, Mangen MJ, Schalm S. High impact of migration on the prevalence of chronic hepatitis B in the Netherlands. Eur J Gastroenterol Hepatol. 2008;20(12):1214–25.CrossRef
39.
go back to reference Dong Z, Hu W, Liu X, Kang Y, Chen C, Fu C. Communicable diseases report quality and survey on influencing factors of Guangzhou medical institutions in 2012. J Med Pest Control. 2014;30(04):370–3. Dong Z, Hu W, Liu X, Kang Y, Chen C, Fu C. Communicable diseases report quality and survey on influencing factors of Guangzhou medical institutions in 2012. J Med Pest Control. 2014;30(04):370–3.
Metadata
Title
Trends in hepatitis B notification rates in Guangzhou, China, between 2009 and 2020: an epidemiological study
Authors
Wei Liu
Zhiqiang Dong
Wensui Hu
Ke Li
Lili Sun
Jianrong Hou
Shijie Jia
Yuan Liu
Publication date
01-12-2022
Publisher
BioMed Central
Keyword
Hepatitis B
Published in
BMC Infectious Diseases / Issue 1/2022
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-022-07690-y

Other articles of this Issue 1/2022

BMC Infectious Diseases 1/2022 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.